A 52-year-old man with CKD stage 4 (eGFR 22 mL/min/1.73m²) due to diabetic nephropathy presents with fatigue and dyspnea on exertion. Hemoglobin is 8.2 g/dL, MCV 78 fL, serum iron 45 µg/dL (normal 60–170), ferritin 320 ng/mL (normal 30–300), and TSAT 18% (normal 20–50%). Reticulocyte count is 0.8% (normal 0.5–2.5%). Serum creatinine is 3.8 mg/dL, calcium 7.8 mg/dL (corrected), phosphate 5.2 mg/dL, and iPTH 285 pg/mL (normal 15–65). What is the primary mechanism responsible for the anemia in this patient?

Explanation

## Pathophysiology of CKD-Related Anemia **Key Point:** The primary cause of anemia in CKD stage 4 is **erythropoietin (EPO) deficiency**, accounting for ~90% of anemia in advanced CKD. ### Why EPO Deficiency Occurs The kidneys produce ~90% of circulating EPO in response to hypoxia sensed by peritubular fibroblasts. As GFR declines: 1. Nephron loss → fewer EPO-producing cells 2. Chronic hypoxia signaling becomes blunted 3. Uremic toxins further suppress EPO production 4. Inflammation (elevated IL-6, TNF-α) inhibits erythropoiesis ### Laboratory Interpretation in This Case | Parameter | Finding | Interpretation | |-----------|---------|----------------| | Hb | 8.2 g/dL | Moderate anemia | | MCV | 78 fL | Microcytic (not macrocytic → rules out B12/folate) | | Iron studies | TSAT 18%, ferritin 320 | **Iron replete** (ferritin elevated, TSAT low-normal) | | Reticulocyte count | 0.8% | **Inappropriately low** for degree of anemia (should be >2% if bone marrow responding) | | iPTH | 285 pg/mL | Elevated (secondary hyperparathyroidism from phosphate retention) | **Clinical Pearl:** The inappropriately *low* reticulocyte count in the setting of anemia is the hallmark of EPO deficiency. The bone marrow is not responding because EPO stimulus is absent, not because iron or B12 is lacking. ### Why Other Options Are Wrong - **Iron deficiency from dialysis loss:** This patient is not yet on dialysis (eGFR 22, not <15). Moreover, ferritin is elevated and TSAT is low-normal, indicating iron repletion, not deficiency. - **B12 malabsorption:** Would cause macrocytic anemia (MCV >100), not microcytic (MCV 78). B12 deficiency is rare in CKD. - **Hemolysis from hyperphosphatemia:** Hyperphosphatemia does not cause hemolysis; it causes vascular calcification and secondary hyperparathyroidism. ### Management Implications **High-Yield:** ESA (erythropoiesis-stimulating agent) therapy is first-line for CKD anemia with EPO deficiency. Iron supplementation is adjunctive only if TSAT <20% or ferritin <100 ng/mL. **Mnemonic: "EPO-CKD"** — **E**rythropoietin **P**roduction **O**ccurs in **C**hronic **K**idney **D**isease loss.